Kopran Ltd

Kopran Ltd Share Price Today: Live Updates & Key Insights

Get insights on Kopran Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Kopran Ltd Share Price Chart

Kopran Ltd Fundamentals

Traded Volume: 1,99,591

Market Cap(Cr): 621

Avg Traded Price 129.95

1 Year return -35.55%

Upper Circuit 133.7

Lower Circuit 128

P/E TTM 35.00

P/B Ratio 4.00

Traded Value(Cr) 256.69

EPS TTM 3.645

Book value 3.645

Dividend 2.00%

Kopran Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Kopran Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Kopran Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -10.19%

1M -23.10%

3M -20.09%

1Y -35.55%

YTD -37.00%

Kopran Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Kopran Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.89L

Day Before Yesterday 3.09L

1W Avg 2.55L

1M Avg 1.96L

3M Avg 2.29L

Kopran Ltd Technical Details

Kopran Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 127

Support 2 124

Support 3 121

Pivot Point : 130

Resistance 1 132

Resistance 2 136

Resistance 3 138

Kopran Ltd Corporate Actions

Kopran Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Kopran Ltd’s capital allocation strategies.

All

Ex-Date 04-Sep-2025 Type D Description 3.00/share@30.00% Record Date 04-Sep-2025 Ratio 30.00

Ex-Date 02-Sep-2024 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 07-Sep-2023 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 04-Aug-2022 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 05-Aug-2021 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 05-Nov-2020 Type D Description 1.50/share@15.00% Record Date 07-Nov-2020 Ratio 15.00

Dividends

Announcement Date 04-Sep-2025 Ex Dividend Date 04-Sep-2025 Dividend(%) 30

Announcement Date 02-Sep-2024 Ex Dividend Date 02-Sep-2024 Dividend(%) 30

Announcement Date 07-Sep-2023 Ex Dividend Date 07-Sep-2023 Dividend(%) 30

Announcement Date 04-Aug-2022 Ex Dividend Date 04-Aug-2022 Dividend(%) 30

Announcement Date 05-Aug-2021 Ex Dividend Date 05-Aug-2021 Dividend(%) 15

Announcement Date 05-Nov-2020 Ex Dividend Date 05-Nov-2020 Dividend(%) 15

Bonus

No Bonus has been declared by KOPRAN

Splits

No Split has been declared by KOPRAN

Others

Rights No Rights has been declared by KOPRAN

Kopran Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Kopran Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Kopran Ltd's relative performance and valuation against major competitors.

Stock Name Accent Microcell Ltd ₹308.20 (-2.88%) M. Cap (Cr) 7.39 1 Yr Return (%) +35.56% P/E (TTM) 22.36 PB Ratio 3.15

Stock Name Kilitch Drugs (India) Ltd ₹368.70 (+1.70%) M. Cap (Cr) 6.45 1 Yr Return (%) +23.09% P/E (TTM) 23.37 PB Ratio 2.56

Stock Name Shree Ganesh Remedies Ltd ₹490.00 (+6.99%) M. Cap (Cr) 6.29 1 Yr Return (%) -26.90% P/E (TTM) 29.73 PB Ratio 4.56

Stock Name Kopran Ltd ₹128.61 (-4.02%) M. Cap (Cr) 6.21 1 Yr Return (%) -35.55% P/E (TTM) 35.29 PB Ratio 1.20

Stock Name Jenburkt Pharmaceuticals Ltd ₹1245.00 (+0.63%) M. Cap (Cr) 5.49 1 Yr Return (%) +10.26% P/E (TTM) 16.63 PB Ratio 3.19

Stock Name Medicamen Biotech Ltd ₹400.80 (-0.88%) M. Cap (Cr) 5.44 1 Yr Return (%) -7.09% P/E (TTM) 53.52 PB Ratio 2.51

Stock Name Vikram Thermo (India) Ltd ₹171.00 (-2.84%) M. Cap (Cr) 5.36 1 Yr Return (%) -1.55% P/E (TTM) 16.12 PB Ratio 5.08

Kopran Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Kopran Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 23.30 Mar 2024 34.96 Mar 2023 16.87 Mar 2022 -37.81 Mar 2021 48.77

PARTICULARS Investing Activities Mar 2025 -15.41 Mar 2024 -6.27 Mar 2023 10.05 Mar 2022 -100.26 Mar 2021 -8.51

PARTICULARS Financing Activities Mar 2025 5.64 Mar 2024 -24.08 Mar 2023 -26.13 Mar 2022 138.00 Mar 2021 -40.14

PARTICULARS Net Cash Flow Mar 2025 13.53 Mar 2024 4.61 Mar 2023 0.79 Mar 2022 -0.07 Mar 2021 0.12

Kopran Ltd Shareholding Pattern

This shows the ownership breakdown of Kopran Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 44.42%

Public 54.99%

Other Institutions 0.0%

FII 0.6%

Mutual Funds null%

About Kopran Ltd

Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.`92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world`s highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran`s bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran`s high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002. The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres. The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos). In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004. Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.

Executive Vice Chairman

Surendra Somani

Registered office Parijat House 1076, Dr E Moses Road Worli, Mumbai, Maharashtra, 400018

FAX :91-22-43661111

Background

Incorporation Year 1958

Face Value ₹10.00

Market Lot 1

Kopran Ltd Latest News

VIEW MORE NEWS

FAQs on Kopran Ltd